Claim · 2021-04-15 · publication · Stated in source · Supported

The letter from Recursion's co-founder and CEO in its IPO prospectus (15 April 2021) states the company's mission as "to Decode Biology to Radically Improve Lives".

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

Recursion Pharmaceuticals, Inc. IPO prospectus (424B4) → states provision → stated mission: "Decode Biology to Radically Improve Lives"

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

Recursion Pharmaceuticals, Inc. IPO prospectus (424B4)states provision ↓stated mission: "Decode Biology to Radically Improve Lives"

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Provision: Statement · provision ID co-recursion-mission-2021
Date: 2021-04-15 · publication Records dated 2021 →

Scope and limitsA company's statement of its own mission; it says nothing about results.

The evidence 01

primary sourceSupports the claim

Recursion Pharmaceuticals, Inc. prospectus (Rule 424(b)(4)), initial public offering of Class A common stock

Recursion Pharmaceuticals, Inc. (filed with the US SEC) · 2021-04-15

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“Our mission is to Decode Biology to Radically Improve Lives.”

Location in source A Letter from our Co-Founder and CEO

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: Recursion Pharmaceuticals, Inc. (filed with the US SEC)
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 487039a60194b9c022cbf378210cd78655434c824bb3d7ae49f77ed721d01b4a). SEC EDGAR 424B4, accession 0001193125-21-119404, filed 2021-04-16; prospectus dated April 15, 2021; as served on 2026-10-30.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: Recursion Pharmaceuticals, Inc. (filed with the US SEC), “Recursion Pharmaceuticals, Inc. prospectus (Rule 424(b)(4)), initial public offering of Class A common stock”, 2021-04-15.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (10 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. An exact framework edition, or another document with an exact expression, states one provision: a capability threshold or risk level and its trigger, a required safeguard or action, a decision authority (who decides, recommends, can overrule or is informed), a stated exception, or another statement of its content, such as a licence term or a prospectus statement. The passage records what the document says, not implementation, compliance or effectiveness. Provisions with the same key align across editions of one family.

Date. Prospectus date.

Record ID aib-co-recursion-mission-2021